![Vinay Prasad MD MPH on X: "The POLO trial is not suited to change practice. As we write in the journal Cancer https://t.co/nn5RnTdYpO https://t.co/BOKyjycSrj" / X Vinay Prasad MD MPH on X: "The POLO trial is not suited to change practice. As we write in the journal Cancer https://t.co/nn5RnTdYpO https://t.co/BOKyjycSrj" / X](https://pbs.twimg.com/media/EiUnbXtU4AAwKpB.jpg:large)
Vinay Prasad MD MPH on X: "The POLO trial is not suited to change practice. As we write in the journal Cancer https://t.co/nn5RnTdYpO https://t.co/BOKyjycSrj" / X
![Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer | Journal of Clinical Oncology Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-34/jco.21.01604/20221116/images/large/jco.21.01604t1.jpeg)
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer | Journal of Clinical Oncology
![Thomas George MD, FACP on X: "O'Reilly: If you have #PancreaticCancer, know your MSI and BRCA status! It could significantly change your treatment plan. #ASCO18 #PancSM https://t.co/kXXTaDdfCx" / X Thomas George MD, FACP on X: "O'Reilly: If you have #PancreaticCancer, know your MSI and BRCA status! It could significantly change your treatment plan. #ASCO18 #PancSM https://t.co/kXXTaDdfCx" / X](https://pbs.twimg.com/media/DeuElcyWsAAWsjC.jpg)